Clinical Trial

Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The investigators hypothesize that graft rejection after hematopoietic stem cell transplant (HSCT) is primarily driven by interferon gamma, and prophylactic interferon gamma inhibition in high-risk patients will prevent graft rejection. Additionally, knowledge of emapalumab PK/PD and in vitro mechanistic effects of emapalumab in this novel setting will guide optimization of dosing regimens and treatment approaches in future studies.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-17.
Status change: Not Yet Recruiting → Recruiting 2026-01-21
Trial Details
NCT Number NCT07244419
Lead Sponsor Children's Hospital Medical Center, Cincinnati
Collaborators: Sobi, Inc.
Conditions Hematopoietic Stem Cell Transplantation, Graft Failure
Enrollment 20 participants
Start Date 2026-01-07
Primary Completion 2029-06 (estimated)
Study Completion 2029-08 (estimated)
Updated on ClinicalTrials.gov 2026-01-22